Related Experiment Video

Updated: Jul 9, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Making it happen: managed care considerations in vanquishing hepatitis C

John G McHutchison1, Bruce R Bacon, Glenda S Owens

  • 1Duke Clinical Research Institute, Duke University Medical Center, P.O. Box 17969, Durham, NC 27715, USA. mchut001@mc.duke.edu

The American Journal of Managed Care
|January 12, 2008
PubMed

Insights

Antiviral treatment for chronic hepatitis C virus (HCV) infection is cost-effective, preventing future liver disease. Improved patient identification and adherence strategies are crucial for maximizing treatment outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Health Economics

Background:

  • Chronic hepatitis C virus (HCV) infection presents significant medical and economic challenges.
  • Patients with HCV utilize substantial and increasing healthcare resources.
  • Existing data suggest antiviral treatment is cost-effective despite initial expenses.

Purpose of the Study:

  • To analyze the cost-effectiveness of antiviral treatment for chronic HCV infection.
  • To identify enhanced methods for patient identification and treatment.
  • To optimize patient care and outcomes for chronic HCV.

Main Methods:

  • Analysis of available data on virologic efficacy.
  • Assessment of treatment impact on patient outcomes.
  • Evaluation of cost-effectiveness of antiviral therapies.

Main Results:

  • Antiviral treatment for chronic HCV is justified by initial costs, leading to future savings.
  • Prevention of liver disease through treatment contributes to overall cost-effectiveness.
  • Enhanced patient identification and treatment strategies are necessary.

Conclusions:

  • Antiviral therapy for chronic hepatitis C virus infection is a cost-effective intervention.
  • Improved clinician awareness, patient education, and adherence monitoring are recommended.
  • Optimizing care pathways can maximize patient outcomes and reduce long-term healthcare burden.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...